Published in Women's Health Weekly, May 4th, 1998
For one of the drugs, the government had a stark message April 22, 1998: Despite headlines trumpeting raloxifene, Eli Lilly's new osteoporosis drug, there is no good evidence yet that the medicine truly wards off breast cancer.
But a National Cancer Institute (NCI) study did find that a related medicine, tamoxifen, cuts the chances of breast cancer by a significant 45 percent in certain women, and the NCI said it is preparing kits to help doctors target...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly